Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations

Nishant P. Shah, Neha J. Pajidipati, Robert W. McGarrah, Ann Marie Navar, Sreekanth Vemulapalli, Michael A. Blazing, Svati H. Shah, Adrian F. Hernandez, Manesh R. Patel

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Lipoprotein (a) [Lp(a)] is a low-density, cholesterol-containing lipoprotein that differs from other low-density lipoproteins due to the presence of apolipoprotein(a) bound to its surface apolipoprotein B100. Multiple epidemiologic studies, including Mendelian Randomization studies, have demonstrated that increasing Lp(a) levels are associated with increased risk of heart disease, including atherosclerotic cardiovascular disease and calcific aortic stenosis. The risk associated with elevations in Lp(a) appears to be independent of other lipid markers. While the current treatment options for elevated Lp(a) are limited, promising new therapies are under development, leading to renewed interest in Lp(a). This review provides an overview of the biology and epidemiology of Lp(a), available outcome studies, and insights into future therapies.

Original languageEnglish (US)
Pages (from-to)94-102
Number of pages9
JournalAmerican Journal of Cardiology
StatePublished - Jul 1 2020
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations'. Together they form a unique fingerprint.

Cite this